Buprenorphine maintenance treatment for opioid dependence may result in hyperalgesia and prevent morphine-associated antinociception.
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
All 3 opioid-dependence pharmacotherapies — methadone, buprenorphine, and oral naltrexone — were associated with reductions in inpatient substance abuse treatment.
Clinical best practice recommendations for the use of buprenorphine in the perioperative management of patients undergoing interventional pain procedures and other surgeries were recently published.
Preliminary results suggest that a new sublingual buprenorphine wafer may offer high bioavailability and fast absorption for patients treated for acute and chronic pain.
Compared to other commonly used opioids, buprenorphine offers a ceiling effect for respiratory depression and less abuse potential, less cognitive impairment, and less constipation.
Methadone exposure in utero was shown to increase the risk for neonatal abstinence syndrome compared with buprenorphine exposure.
In a press release issued November 30, 2017, the US Food and Drug Administration announced it has approved Sublocade, a once-monthly buprenorphine injection for moderate to severe opioid use disorder.
Compared with buprenorphine-naloxone, use of extended-release naltrexone maintained abstinence from heroin and other illicit substances at a similar rate.
Patients can be transitioned from transdermal to buccal formulations of buprenorphine within 12 hours of patch removal using the recommended buccal formulation titration doses and schedule.
Significantly less heroin cravings were reported in the extended-release naltrexone group and treatment satisfaction was also reported higher in this group compared to the buprenorphine-naloxone group.
The FDA has recently issued a report advising against the use of buprenorphine and methadone medications in patients taking benzodiazepines and/or other central nervous system depressants.
The extended-release formulation of tramadol was shown to be as effective as buprenorphine and more effective than clonidine for treating symptoms of opioid withdrawal.
Once-weekly subcutaneous buprenorphine injections block the euphoric effects of opioids and suppress opioid withdrawal in patients with opioid use disorder.
Early pharmacologic intervention for opioid use disorder after diagnosis is crucial to prevent relapse and overdose in adolescents and young adults.
Discrepancies in Subjective vs Objective Sleep in Patients Receiving Buprenorphine for Opioid Use DisorderJune 20, 2017
Patients receiving buprenorphine maintenance therapy for their opioid use disorder may have impaired sleep, despite their reports of improved quality and duration of sleep.
Changes in several measures of pain in patients suspected of opioid-induced hyperalgesia were observed after transitioning from opioids to buprenorphine.
Substance Use Disorder is a chronic medical condition, and should be treated like one.
Teenagers with prescription opioid exposures are more likely to have health care facility admission and serious medical outcomes than younger children.
Pennsylvania has adopted a multipronged approach to address the opioid crisis.
Buprenorphine/naloxone treatment initiated in the emergency department and prolonged for 10 weeks in primary care improved treatment engagement and reduced opioid use compared with referral or brief intervention.
Patients addicted to opioids treated in a hospital emergency department do better when they receive medication to reduce opioid cravings.
An 8-day detoxification process using low-dose oral naltrexone showed superior efficacy to the standard 15-day approach that uses an agonist taper leading to induction with extended-release naltrexone
Throughout 2016, the FDA has announced requirements for manufacturers to create new product labeling information for a variety of opioid medications.
The initiatives include guidelines and recommendations for CRNAs, physicians, and policymakers.
The researchers found that novice prescribers cited insufficient access to substance abuse counseling for patients, as well as insufficient access to more experienced prescribers, as reasons for not treating more patients.
There is a lot of opportunity to improve on what can be offered to patients.
Buprenorphine implants could help improve relapse prevention in patients who are currently maintaining abstinence with sublingual buprenorphine
When tolerated, buprenorphine is effective for diabetic peripheral neuropathic pain
Improved delivery method for buprenorphine
Clinical Pain Advisor Articles
- Reviewing the Efficacy, Safety, and Tolerability of Cannabis-Based Medicines for Chronic Neuropathic Pain
- Femoral Nerve Block Alone or in Combination With Sciatic Nerve Block for TKA: A Meta-Analysis
- Tackling the Chronic Pain and Opioid Use Disorder Crises Through Public-Private Partnerships
- How the City of San Francisco Is Tackling the Intertwined HIV/HCV and Opioid Epidemics
- Pain Tolerance in Buprenorphine Maintenance Treatment
- Radiofrequency Ablation for Chronic Hip Pain: Reviewing the Evidence
- Opioid Use Disorder Treatment: Evidence-Based Guideline
- Betel Quid Addiction and Implications for Substance Use Disorder
- Low Back Pain: Contributing Factors, Prophylactic Strategies, and Effective Treatments
- Peripherally Acting Opioid and Cannabinoid May Be Effective for Neuropathic Pain
- Transcranial Magnetic Stimulation May Prevent Migraine in Adolescents
- Widespread Impact of Reducing Opioids, Adding IV Acetaminophen for Postsurgical Pain Management
- GI Safety Compared for NSAIDs in Patients With Arthritis
- Opioid Prescribing Trends in Patients With, Without Cancer
- DOJ Rescinds Protections Afforded by Americans With Disabilities Act